-
平臺(tái)編號(hào)：bio-49963
-
國(guó)際編號(hào)：ATCC VR-1566
-
拉丁屬名： Vaccinia virus
-
規(guī)格：frozen
-
用途：ATCC原裝進(jìn)口
-
服務(wù)費(fèi)用：
加載中…… - 訂購(gòu)
-
注意事項(xiàng)：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動(dòng)物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫(kù)為準(zhǔn)）
中文名稱暫無(wú)
Vaccinia virus 拉丁名
ATCC VR-1566 編號(hào)
Classification Poxviridae, Orthopoxvirus
Agent Vaccinia virus
Strain Modified vaccinia virus Ankara (MVA)
Biosafety Level 安全等級(jí) 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Isolation 分離基物 Attenuated vaccine strain
Product Format 提供形式 frozen
Storage Conditions -70°C or colder (or colder)
Effect on Host
Yes, Cytopathic effect: Rounding and death of infected cells.
CPE with cell rounding and cell death
Growth Medium The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: tryptose phosphate broth to a final concentration of 5% and fetal bovine serum to a final concentration of 5%.
Recommended Host
Recommended Host: CEF (ATCC # CRL-1590)
Alternate Host(s): BHK-21 (ATCC # CCL-10)
Growth Conditions 生長(zhǎng)條件
Temperature 培養(yǎng)溫度 : 37.0°C
Duration: 2-6 days to 3-4+ CPE when inoculated onto cells at 80-90% confluence in a T-225 flask.
Cryopreservation
Storage temperature: -70 C
Effect on Host
Yes, Cytopathic effect: Rounding and death of infected cells.
CPE with cell rounding and cell death
Name of Depositor LS Wyatt, B Moss, A Mayr
Special Collection ATCC
Source
Attenuated vaccine strain
References 參考文獻(xiàn)
Antoine G, et al. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244: 365-396, 1998. PubMed: 9601507
Sutter G, Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA 89: 10847-10851, 1992. PubMed: 1438287
Meyer H, et al. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 72: 1031-1038, 1991. PubMed: 2033387
Mahnel H, Mayr A. Experiences with immunization against orthopox viruses of humans and animals using vaccine strain MVA. Berlin Munch. Tierarztl. Wochenschr. 107: 253-256, 1994.
Mayr A, et al. Abstammung, eigenschafter und verwendung des attenuierten vaccinia-stammes. Infection 3: 6-14, 1975.
Rotz LD, et al. Vaccinia (Smallpox) Vaccine Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. Morb. Mortal. Wkly. Rep. 50: 1-25, 2001.
or colder
Wyatt LS, et al. Marker rescue of the host range restriction defects of modified vaccinia virus Ankara. Virology 251: 334-342, 1998. PubMed: 9837798
MVA was isolated by serial passage of CVA (Ankara) strain in chick embryo fibroblasts (CEF) in the laboratory of Professor Anton Mayr, then given to the National Insitutes of Health, where it was plaque purified three times in CEF cells. VR-1566 was derived by limited further passage of stock received from the NIH in the SL-29 chicken embryo fibroblast cell line [ATCC CRL-1590].
or colder
Cross References
Nucleotide (GenBank) : U94848 Vaccinia virus strain Ankara, complete genomic sequence.
